Introduction {#S0001}
============

DNA methylation, an important regulation mechanism of gene expression, is a critical epigenetic modification which is not based on DNA sequence changes. DNA aberrant methylation commonly occurs in the CpG island region of the tumor suppressor gene.[@CIT0001] It has been found that the abnormal methylation of tumor suppressor genes affects the various malignant biological characteristics.[@CIT0002],[@CIT0003] Moreover, the CpG island of promoter methylation is often related to prognosis.[@CIT0004] As an important tumor suppressor gene family in homo sapiens, RNF (Ring Finger Protein) genes are involved in the construction of E3 ubiquitin protein ligase in ubiquitin proteasome system (UPS), which are also involved in ubiquitin degradation.[@CIT0005] It has been found that RNFs participate in a variety of cellular processes including DNA repair, gene transcription and apoptosis.[@CIT0006] The disorder of UPS often occurs in various tumors, which leads to tumorigenesis.[@CIT0007] RNF180 is a tumor suppressor gene that encodes the ubiquitin ligase E3 RING structure protein.[@CIT0008] Its function covers various biological behaviors such as cell proliferation, apoptosis, differentiation and tumor formation by affecting the protein ubiquitination degradation.[@CIT0008] Inactivation of RNF180 is related to apoptosis, tumor invasion and metastasis.[@CIT0009]

Gastric cancer (GC) is a malignant tumor that seriously threatens human health. The incidence rate of gastric cancer ranks fifth in malignant tumor worldwide. And the third leading cause of cancer-related death.[@CIT0010] Our previous study found that the methylation level of RNF180 promoter region was related to gastric tumorigenesis.[@CIT0011] According to the results of our previous work, a series of highly frequent-methylated CpG sites were considered to be highly associated with atrophy gastritis (AG) and GC, which are M3(−165)(Chr5:64,165,942), M5(−148)(Chr5:64,165,959), M7(−133)(Chr5:64,165,974), M8(−130)(Chr5:64,165,977), M20(−57)(Chr5:64,166,050), M25(−34)(Chr5:64,166,073), M27(−26)(Chr5:64,166,081) and M30(+5)(Chr5:64,166,112). Risk analysis indicated that increased methylation rate at multiple CpG sites could significantly increase the risk of GC, suggesting that methylation of RNF180 CpG sites in the promoter region could be used as a molecular marker for prediction and early diagnosis of GC. However, it is not clear whether these key sites could affect gene expression and involve in prognosis. This study focused on the methylation of specific CpG sites in RNF180 promoter region to evaluate the correlation of gene expression, and combined with clinical and prognostic information to discuss the feasibility of methylation as a molecular biomarker for GC prognosis.

Patients and Methods {#S0002}
====================

Patients and Tissue Samples {#S0002-S2001}
---------------------------

A total of 164 GC patients were enrolled in the First Hospital of China Medical University, Shenyang, China, from 2011 to 2015, including 112 males and 52 females with average ages of 60.2±10.7 and 56.9±12.6 years, respectively. The tumor tissues were collected from patients who underwent surgical resection within 30 mins. Among them, tumor-adjacent non-cancerous tissues in 80 cases were also collected meanwhile. Tissue samples were frozen at --80°C until DNA and RNA extraction. Two gastrointestinal pathologists were invited to evaluate the pathologic diagnosis for all cases independently in accordance with the WHO classification and updated Sydney System. Epidemiological information and clinical-pathological data were collected by questionnaires and computerized medical records. After surgery, all subjects were followed up every 6 months at the outpatient department or by telephone until the patient died. The follow-up period was from August 2012 to March 2018. Median follow-up time was 35.5 months. This study was approved by the Human Ethics Review Committee of the First Hospital of China Medical University (Shenyang, China). Written informed consent was provided to all patients. All consent progress was conducted in accordance with the Declaration of Helsinki. The Ethical Review Committee number of this study was 2016 No.2016-155-2.

DNA Extraction {#S0002-S2002}
--------------

Tissue DNA was extracted according to chloroform/phenol extraction procedure as follows: take 50 mg fresh tissue, cryogenic grinding, add lysate (400 ul Tris-EDTA (Cat. PH0620, Phygene China) + 25 μL, 10% Sodium dodecyl sulfate (SDS, Sigma US)+10μL Proteinase K(Cat. P2308 Sigma US)), mix and digest overnight in 37°C. On the next day, phenol and chloroform were added to extract diluted DNA. Absolute ethanol was used to precipitate DNA. At last genomic DNA was diluted by using Tris-EDTA and stored at −20°C during the experiment.

Bisulfite Sequencing PCR {#S0002-S2003}
------------------------

Bisulfite sequencing PCR (BSP) was used as a quantitatively analyzed method for detecting the methylation rate of the RNF180 promoter area. The gene sequence for this study was obtained from Genebank. The MethylKIT package ([<http://www.bioconductor.org/packages/release/bioc/html/methylKit.html>]{.ul}) of R software was used to analyze methylation data, all CpG sites and transcription initiation site (TSS). Genomic DNA sodium bisulfite modification was performed by Zymo DNA Methylation-Gold kit (Cat. Nos. D5005 or D5006, Zymo Research, US) according to the manufacturers' instructions. Polymerase chain reaction (PCR) was performed by the enzyme TaKaRa Taq™ Hot Start Version (Code No. R007A Takara, Japan). The primers were as follows: F:5′-GTGGTTTTGGTAAGGGGATGAT-3′; R: 5′-AACAACCAAACTCTAAAAACTC-3′.[@CIT0011] The condition was as follows: 94°C for 3 mins for initial denaturation, run 45 cycles (94°C 20 s, 58.5°C 30 s, 72°C 45 s); after the end of the cycles followed by an extension 10 mins at 72°C, a final termination at 4°C. PCR purification products were used for forward sequence analysis. Chromas version 2.6.6 (Technelysium Pty Ltd., Australia) was used to analyze sequencing results. According to the theory of bisulfite modification, methylation rate calculation formula was as follows: Meth%=C/(C+T)\*100%.[@CIT0012]

RNA Extraction {#S0002-S2004}
--------------

Tissue RNA was extracted with the Animal Tissue Total RNA Extraction Kit (TIANGEN, DP431, CHINA). A 1μg total RNA was reversed transcribed into cDNA using the Fast Quant cDNA First-Strand Synthesis Kit (TIANGEN, KR106). RNA extraction and reverse transcription were performed according to the instructions.

Quantitation Real-Time Polymerase Chain Reaction (RT-qPCR) {#S0002-S2005}
----------------------------------------------------------

The expression level of RNF180 mRNA was detected by RT-qPCR. The primers were as follows: Forward: 5ʹ-TCTGACTTTCCTGATGGACCTG-3ʹ, Reverse: 5ʹ-CCTGAGTATTTACCCTGCTTCTGT-3ʹ. GAPDH was used as a control. The primers were as follows: Forward: 5ʹ-TGCACCACCAACTGCTTAG-3ʹ, Reverse: 5ʹ-GGATGCAGGGATGATGTTC-3ʹ. PCR reaction mix is 20 μL in total. PCR reaction system contains SYBR^®^ Premix Ex TaqTMII 10 ul (TaKaRa, Japan), primers (0.8 μL each) and cDNA template (2 μL). PCR cycling conditions were as follows: initial denaturation at 95°C for 30 s, followed by 40 cycles (95°C for 15 s, 55°C for 30 s, 72°C for 30 s). Using 2-^ΔΔCT^ for data statistics.

Transcription Factors (TFs) Binding Sites Prediction {#S0002-S2006}
----------------------------------------------------

JASPAR ([<http://jaspar.genereg.net/>]{.ul}) and PROMO ([<http://alggen.lsi.upc.es>]{.ul}) databases were used to analyze protein and DNA binding sites. Promoter sequence of RNF180 was import into JASPAR and PROMO datasets. The intersection of two datasets is the predicted TFs.

Statistical Analysis {#S0002-S2007}
--------------------

Mann--Whitney *U*-test was used to compare the difference of methylation between GC and control. Student's *T* test, two-tailed, was used to compare the difference of expression between GC and control. Spearman correlation test was used to analyze the correlation between methylation and expression. Survival analysis was performed using Kaplan-Meier. Multi-factor regression survival analysis was performed using COX regression. Log-rank test was used to determine significance. Hazard ratios (HR) and 95% CI were generated at the same time. All analyses were performed using SPSS software (version 19.0 Chicago III) and R software (version 3.3.1 2016 R). Survival package and survminer package were used to perform the cox regression and plot the survival curve. *P* \< 0.05 was considered statistically significant.

Results {#S0003}
=======

Methylation Sequencing Results of RNF180 {#S0003-S2001}
----------------------------------------

A 318 bp fragment was amplified covering −224 to +94 in RNF180 promoter region. Two samples, which were GC tissue and adjacent normal tissue, are listed in [Figure 1A](#F0001){ref-type="fig"} and B. Four pairs of methylation rate analysis results are shown in [Figure 1C](#F0001){ref-type="fig"} (N1 to N4, T1 to T4).Figure 1(**A**) A case of gastric cancer hypermethylation sequencing results. (**B**) A case of normal hypomethylation sequencing results. (**C**) Methylation detection results of RNF180 promoter region in GC and normal. TSS: transcription initiation site. For the reason of readable area, we amplified 318bp from −224 to +94 but only shown readable sequencing with CpG sites from −207 to 94.

Methylation Level of RNF180 Promoter Region Significantly Increased in GC {#S0003-S2002}
-------------------------------------------------------------------------

In 80 pairs of GC and adjacent normal tissues, we analyzed the differences in the methylation rate of RNF180. The average methylation rate (AMR) of RNF180 in GC tissues was significantly higher than that in adjacent non-cancerous tissues, with AMRmedian-GC=0.30(0.22,0.48) and AMRmedian-CON=0.21(0.07, 0.33)(P \<0.001). Eight high frequent-hypermethylated CpG sites as follows, which were identified in our previous study: M3(−165)(Chr5:64,165,942), M5(−148)(Chr5:64,165,959), M7(−133)(Chr5:64,165,974), M8(−130)(Chr5:64,165,977), M20(−57)(Chr5:64,166,050), M25(−34)(Chr5:64,166,073), M27(−26)(Chr5:64,166,081), M30(+5)(Chr5:64,166,112). ([Table 1](#T0001){ref-type="table"}).Table 1Methylation Rate Difference Between GC and ControlNameLocation in Chr.Location in RNF180nMedian (25th,75th)*P* valueGCControlAverageChr5: 64,165,883 to 64,166,201−224 to +94800.30(0.22,0.48)0.21(0.07,0.33)7.64E-05M3Chr5: 64,165,942−1650.45(0.17,0.57)0.15(0.08,0.39)3.86E-06M5Chr5: 64,165,959−1480.33(0.19,0.52)0.17(0.09,0.36)1.94E-04M7Chr5: 64,165,974−1330.50(0.24,0.60)0.18(0.09,0.44)1.56E-07M8Chr5: 64,165,977−1300.45(0.20,0.54)0.16(0.08,0.42)1.41E-06M20Chr5: 64,166,050−570.44(0.18,0.57)0.19(0.07,0.46)4.25E-05M25Chr5: 64,166,073−340.65(0.40,0.79)0.37(0.17,0.57)1.60E-06M27Chr5: 64,166,081−260.44(0.18,0.66)0.30(0.14,0.50)1.82E-03M30Chr5: 64,166,11150.58(0.27,0.68)0.23(0.13,0.55)8.09E-05[^2]

The Expression Level of RNF180 mRNA Decreased in GC {#S0003-S2003}
---------------------------------------------------

In 80 pairs of GC and adjacent normal tissues, we analyzed the differences of RNF180 mRNA expression between GC and adjacent normal tissues. The expression of RNF180 was significanly downregulated in GC tissues compared to adjacent non-cancerous tissues. (*P*=3.35E-4, [Figure 2](#F0002){ref-type="fig"}).Figure 2RNF180 mRNA expression difference (N~normal~=80 N~cancer~=80 *P* value=3.35E-04 \*\*\*p \< 0.001 Mann--Whitney *U*-test by using Normalized 2^−ΔΔCt^).

The Methylation of RNF180 Was Negatively Correlated with Gene Expression {#S0003-S2004}
------------------------------------------------------------------------

In order to investigate the effect of aberrant methylation on RNF180 expression, we analyzed the correlation between methylation rate and mRNA expression. There was negative correlation between AMR and mRNA expression in GC tissues (r~AMR-GC~ = −0.238, *P*~AMR-GC~ = 0.033), but not in adjacent non-cancerous tissues. Further we found 4 CpG sites related to gene expression, including M3(−165)(Chr5:64165942), M5(−148)(Chr5:64165959), M7(−133)(Chr5:64165974), M8(−130)(Chr5:64165977), the trends of which were consistent with AMR. Curiously, for M27(−26)(Chr5:64166081), there was large negative correlation coefficient between methylation and expression in GC (r=−0.941), but with no statistical significance (*P*=0.084) ([Table 2](#T0002){ref-type="table"}). Considering that statistical differences may be affected by total sample size, we still consider recruiting M27(−26)(Chr5:64166081) in our further survival analysis.Table 2Correlation Between RNF180 Expression and Methylation RateCpG SitesnGCControlr*\*P* valuer*\*P* valueAMR80−0.2380.033−0.1020.366M3−0.3090.005−0.1100.331M5−0.2790.012−0.0670.552M7−0.2910.009−0.0700.540M8−0.3140.005−0.1050.352M20−0.1560.167−0.0440.701M25−0.1390.219−0.0390.732M27−0.9410.084−0.0400.727M30\<0.0010.999−0.1540.172[^3]

No Significant Correlation Between RNF180 Methylation and Clinical Information {#S0003-S2005}
------------------------------------------------------------------------------

We analyzed the correlation between RNF180 methylation and clinical information in 164 GC cases, including gender, age, smoking, lymph node metastasis, histologic differentiation, vascular cancer embolus, lauren's classification, growth pattern, invasioin depth, metastasis and TNM stages. For AMR and M27(−26)(Chr5:64166081), the methylation rate was different in TNM staging groups, but it was not statistically significant(P=0.06,P=0.054). No significant relationships were found with other sites or clinical parameters. ([Table 3](#T0003){ref-type="table"}).

Methylation Rate Greater Than 0.3 Could Predict the Prognosis of GC {#S0003-S2006}
-------------------------------------------------------------------

We used R packages to analyze the best cut-off value of the methylation rate for GC survival. The results showed that methylation rate \>0.3 could be a best prognosis indicator in M5(−148)(Chr5:64,165,959), M27(−26)(Chr5:64,166,081) (*P*~M5(−148)~ = 0.012;*P*~M27(−26)~ = 0.002). In other words, a methylation rate greater than 0.3 suggested a poor prognosis ([[supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=246995.docx)]{.ul}). Although a methylation rate \>0.8 demonstrated poor prognosis in M3(−165)(Chr5:64,165,942), M7(−133)(Chr5:64,165,974), M8(−130)(Chr5:64,165,977), the positive cases were few. The practical significance was not obvious. We did not include these sites in the subsequent analysis.

Methylation Rate Greater Than 0.3 Could Be an Independent Factor to Predict the Prognosis of Gastric Cancer {#S0003-S2007}
-----------------------------------------------------------------------------------------------------------

In order to evaluate the efficacy of RNF180 methylation in predicting prognosis of GC, we further analyzed the impact of methylation rate on survival for AMR, M3(−165)(Chr5:64,165,942), M5(−148)(Chr5:64,165,959), M7(−133)(Chr5:64,165,974), M8(−130)(Chr5:64,165,977), M27(−26)(Chr5:64,166,081). The following clinical factors were used in univariate survival analysis and multivariate COX regression sequentially, including smoke, lymph node metastasis, histological differentiation, growth pattern, vascular cancer embolus, invasion depth, TNM stage and metastasis were included. The results showed methylation rate of M5(−148)(Chr5:64,165,959) and M27(−26)(Chr5:64,166,081) \>0.3 could be independent risk factors for poor prognosis (*P*~M5(−148)~ = 0.008, *P*~M27(−26)~ = 0.003, HR~M5(−148)~ = 2.000(1.201,3.332), HR~M27(−26)~=2.389(1.336,4.271)).([Table 4](#T0004){ref-type="table"}, [Figure 3](#F0003){ref-type="fig"}).Table 3Association Between Methylation Rate of RNF180 and Clinicopathological Parameters in GCVariabilitynAMRM3M5M7M8M27Median (25th,75th)*\*P* valueMedian (25th,75th)*\*P* valueMedia(25th,75th)*\*P* valueMedia(25th,75th)*\*P value*Media(25th,75th)*\*P value*Media(25th,75th)*\*P value*Gender0.7320.7830.8010.5900.6540.753 Male1120.28(0.18,0.38)0.43(0.13,0.55)0.31(0.14,0.52)0.44(0.15,0.56)0.41(0.13,0.52)0.38(0.14,0.60) Female520.27(0.11,0.35)0.40(0.11,0.56)0.26(0.12,0.53)0.40(0.09,0.58)0.39(0.12,0.50)0.38(0.18,0.58)Age0.7310.3380.9990.8050.6940.289 \>60960.29(0.14,0.39)0.45(0.13,0.56)0.29(0.13,0.52)0.43(0.14,0.56)0.40(0.12,0.52)0.40(0.16,0.61) ≤60680.28(0.18,0.36)0.40(0.15,0.53)0.32(0.12,0.51)0.45(0.14,0.56)0.40(0.14,0.50)0.33(0.16,0.54)Smoking0.5630.4430.3750.5640.7600.711 Yes560.30(0.18,0.41)0.37(0.13,0.55)0.35(0.12,0.52)0.40(0.14,0.55)0.42(0.12,0.52)0.41(0.19,0.60) No1080.27(0.15,0.36)0.45(0.14,0.56)0.26(0.13,0.50)0.44(0.12,0.58)0.40(0.13,0.51)0.37(0.15,0.58)Lymph node metastasis0.3050.120.5750.5360.8590.102 Positive1010.30(0.13,0.39)0.37(0.13,0.54)0.34(0.13,0.53)0.42(0.12,0.56)0.39(0.12,0.52)0.41(0.18,0.61) Negative630.26(0.18,0.36)0.49(0.17,0.56)0.28(0.12,0.50)0.48(0.16,0.56)0.43(0.17,0.51)0.34(0.14,0.56)Histologic differentiation0.3170.8720.5480.3140.9720.253 Well690.27(0.12,0.35)0.44(0.10,0.57)0.30(0.11,0.52)0.38(0.13,0.55)0.39(0.10,0.51)0.34(0.15,0.57) Poorly950.28(0.18,0.39)0.43(0.14,0.54)0.33(0.18,0.52)0.44(0.14,0.57)0.41(0.14,0.51)0.41(0.17,0.60)Vascular cancer embolus0.0370.2140.1180.1320.2860.039 Positive440.32(0.23,0.46)0.46(0.28,0.56)0.36(0.20,0.54)0.49(0.32,0.58)0.43(0.22,0.53)0.45(0.25,0.67) Negative1200.27(0.12,0.35)0.41(0.11,0.55)0.28(0.12,0.50)0.42(0.11,0.55)0.39(0.11,0.51)0.35(0.15,0.55)Lauren's classification0.7720.5930.3910.3570.9550.723 Intestinal-type960.28(0.18,0.38)0.42(0.14,0.54)0.29(0.16,0.48)0.44(0.13,0.58)0.40(0.13,0.52)0.39(0.15,0.60) Diffuse-type680.28(0.14,0.37)0.45(0.12,0.57)0.32(0.11,0.58)0.40(0.14,0.55)0.40(0.12,0.51)0.36(0.18,0.56)Growth pattern0.4220.9420.8220.7970.9090.542 Expanding570.24(0.13,0.36)0.43(0.11,0.56)0.30(0.12,0.51)0.40(0.11,0.56)0.39(0.12,0.51)0.34(0.15,0.58) Infiltrative1070.30(0.18,0.39)0.44(0.14,0.55)0.33(0.14,0.52)0.44(0.14,0.56)0.41(0.13,0.52)0.41(0.16,0.60)Invasion depth0.2320.1360.2720.3830.9530.195 T1/T2840.28(0.13,0.34)0.41(0.10,0.53)0.28(0.12,0.50)0.43(0.10,0.56)0.42(0.12,0.50)0.34(0.15,0.57) T3/T4800.29(0.18,0.42)0.45(0.15,0.56)0.33(0.16,0.56)0.45(0.24,0.56)0.39(0.13,0.52)0.42(0.16,0.60)Metastasis0.8640.0620.4280.0680.4490.831 Positive660.29(0.12,0.37)0.31(0.10,0.54)0.34(0.13,0.54)0.37(0.11,0.54)0.37(0.12,0.50)0.40(0.18,0.58) Negative980.28(0.19,0.38)0.46(0.19,0.56)0.29(0.15,0.48)0.48(0.18,0.57)0.42(0.14,0.51)0.37(0.15,0.60)TNM Stages0.0670.2850.8160.7030.6970.054 I230.23(0.19,0.29)0.49(0.28,0.56)0.28(0.19,0.46)0.48(0.23,0.56)0.45(0.19,0.51)0.22(0.14,0.43) II330.27(0.17,0.33)0.51(0.14,0.57)0.23(0.11,0.49)0.42(0.29,0.57)0.46(0.16,0.53)0.34(0.17,0.52) III1060.30(0.12,0.40)0.38(0.11,0.53)0.34(0.13,0.54)0.43(0.11,0.55)0.37(0.11,0.51)0.42(0.17,0.63) IV2\\\\\\\\\\\\Total1640.28(0.17,0.37)\\0.43(0.13,0.56)\\0.31(0.13,0.52)\\0.44(0.14,0.56)\\0.40(0.13,0.51)\\0.38(0.16,0.59)\\[^4] Table 4Survival Analysis Combined with Clinical Parameter and MethylationVariabilitynUnivariateMultivariateHR(95% CI)*P* valueHR(95% CI)*P* valueGender Male1121(Ref.) Female521.128(0.659,1.930)0.661Age \>60961(Ref.) ≤60681.291(0.781,2.134)0.320Smoking No1081(Ref.) Yes561.561(0.947,2.575)0.081Lymph node metastasis Negative631(Ref.)1(Ref.) Positive1015.913(2.815,12.418)0.000002683.188(1.271,7.996)0.013Histological differentiation Well691(Ref.) Poorly950.652(0.387,1.099)0.109vascular cancer embolus Positive441(Ref.)1(Ref.) Negative1201.711(1.025,2.857)0.0401.498(0.855,2.624)0.158Lauren's classification intestinal-type961(Ref.) Diffuse-type680.824(0.495,1.374)0.459Growth pattern Expanding571(Ref.)1(Ref.) Infiltrative1070.555(0.315,0.997)0.0412.120(4.386,1.025)0.043Invasion depth T1/T2841(Ref.) T3/T4800.899(0.551,1.468)0.670Metastasis Negative981(Ref.)1(Ref.) Positive662.096(1.280,3.434)0.0031.018(0.504,2.055)0.960TNM Stages I/II561(Ref.)1(Ref.) III/IV1085.657(2.576,12.420)0.000015713.269(1.389,7.696)0.007AMR ≤0.3931(Ref.)1(Ref.) \>0.3711.832(1.118,3.000)0.0161.940(1.165,3.230)0.011M5 ≤0.3811(Ref.)1(Ref.)^a^ \>0.3832.423(1.371,4.280)0.0021.874.(1.099,3.182)0.021 M27 ≤0.3661(Ref.)1(Ref.)^a^ \>0.3981.885(1.136,3.130)0.0132.441(1.362,4.371)0.003[^5] Figure 3Methylation rate (MR) of specific sites show differential clinical outcomes. A total of 164 cases recruit in our study. (**A**) Cox Regression of AMR \>0.3 shows poor prognosis (*P* = 0.011). (**B**) Cox Regression of M5(−148)~MR~ \>0.3 shows poor prognosis (*P* = 0.021). (**C**) Cox Regression of M27(−26)~MR~ \> 0.3 shows poor prognosis (*P* = 0.003).

Transcription Factors Binding Sites Prediction {#S0003-S2008}
----------------------------------------------

We used JASPAR and PROMO datasets to predict the binding sites with transcript factors. M5(−148)(Chr5:64,165,959) and M27(−26)(Chr5:64,166,081) bind to many transcription factors (TFs), such as FOXA1, FOXC1, FOXC2, FOXF2, FOXP1, EGR1, EGR2 and EGR3, etc. ([[supplementary Table 2](https://www.dovepress.com/get_supplementary_file.php?f=246995.docx)]{.ul}).

Discussion {#S0004}
==========

It is generally believed that the malignant behavior of molecular biology precedes the appearance of the pathological phenotype of malignant tumors.[@CIT0013] DNA methylation plays an important role in tumorigenesis.[@CIT0014] They believe that methylation has broad application prospects as a biomarker. As decades passed, many researchers have made on the feasibility of DNA methylation as a molecular biomarker.[@CIT0015] It has been clarified that promoter methylation of the tumor suppressor gene is often negatively correlated with its expression.[@CIT0016] Demethylation treatment can significantly inhibit the malignant biological behavior of tumors.[@CIT0017] The methylation degree of specific gene region is directly related to lymph node metastasis, TNM stage, tumor pathological classification and prognosis.[@CIT0018] These findings open the door to molecular diagnosis for cancers. We can detect specific methylation sites as molecular biological indicators to predict tumor prognosis.[@CIT0019],[@CIT0020]

RNF180 plays an important role, as a tumor suppressor gene involved in various cellular biological processes, such as DNA repair, gene transcription, apoptosis, etc.[@CIT0005] In our previous study, we found that the methylation rate of RNF180 promoter gradually increased with the severity of gastric mucosal lesions from gastritis, atrophy gastritis to GC. Moreover, we located eight CpG sites in RNF180 promoter with high methylation distribution frequency. However, it is not clear whether specific methylated sites affect the expression of RNF180 in these sites, resulting in a poor prognosis. In this study, we explicitly locate the high-specific methylation sites in the RNF180 promoter region and clarify that the M5(−148)(Chr5:64,165,959) and M27(−26)(Chr5:64,166,081) locus methylation rate can independently determine the prognosis.

We firstly examined the correlation between methylation and mRNA level with GC and adjacent tissue samples. The results showed that compared with the adjacent tissues, the AMR of RNF180 in GC tissue was significantly increased. Moreover, there was a negative correlation between mRNA expression and AMR. In addition, there were five CpG sites: M3(−165)(Chr5:64,165,942), M5(−148)(Chr5:64,165,959), M7(−133)(Chr5:64,165,974), M8(−130)(Chr5:64,165,977), M27(−26)(Chr5:64,166,081), which were negatively correlated with mRNA expression. As an important tumor suppressor gene, RNF180 is an essential RING protein with the function of E3 ubiquitin ligase, the most important protein complex in UPS.[@CIT0008],[@CIT0021] The down-expression of RNF180 would lead to dysfunction of E3 and disorder of UPS.[@CIT0009] It is well known that abnormal UPS can terminate the normal protein degradation process, cause the disorder of tumor metabolism, and promote multiple malignant biological behaviors of tumor cells eventually.[@CIT0007] Therefore, we supposed that hypermethylation in RNF180 promoter region promoted the occurrence and development of GC by down-regulating gene expression level.

Methylation can affect transcription through multiple mechanisms.[@CIT0022] It is generally known that promoter methylation alters the structure of chromatin,[@CIT0023] and has a negative effect in a variety of diseases such as metabolic abnormalities, Alzheimer,[@CIT0024] aging and tumor.[@CIT0025] Gene expression depends on the binding of TFs (TFs) to promoter-specific regions.[@CIT0026],[@CIT0027] CpG sites methylation in these regions interfere with gene expression and affect the binding of TFs to these regions.[@CIT0028] Hypermethylation of promoter of the tumor suppressor gene leads to the down-regulation of gene expression,[@CIT0029] which further leads to tumor development and progression.[@CIT0030] For the above reasons, hypermethylation of tumor suppressor genes can lead to poor prognosis for tumor patients.[@CIT0031]

In order to analyze the methylation and prognosis, we analyzed the relationship between the methylation rate of the above five sites and the prognosis of GC. The results showed that the methylation rate of M5(−148)(Chr5:64,165,959) and M27(−26)(Chr5:64,166,081) could indicate poor prognosis by setting a cut-off value of 0.3. Furtherly, considering the effect of clinical-pathological parameters, we comprehensively analyzed the clinical data of GC, including gender, age, smoking, lymph node metastasis, histological differentiation, vascular cancer embolus, Lauren's classification, growth pattern, invasion depth, distant metastasis and TNM stage. After adjusting for clinical factors, the methylation rates of M5(−148)(Chr5:64,165,959) and M27(−26)(Chr5:64,166,081), with a cut-off value of 0.3, were still independent prognostic factors of GC. Many researchers have found that specific methylation sites can be biomarkers for various tumors.[@CIT0032] STEP1 promoter methylation rate could be a sensitive and specific biomarker for colorectal cancer.[@CIT0033],[@CIT0034] Another research has implied that −1415 CpG site in the promoter of RUNX3 contributes to poor prognosis. This specific site could be a prognostic biomarker in GC.[@CIT0018] In this study, we located two sites as prognostic factors of GC, which may also be binding sites of various transcript factors.

Studies have reported that TFs can bind to specific sequences of DNA, especially some important functional CpG sites.[@CIT0035],[@CIT0036] Abnormal methylation sites can affect TFs binding and lead to abnormal gene function.[@CIT0037] In this study, using JASPAR and PROMO database, we found some TFs, such as FOXA1, FOXC1, FOXC2, FOXF2, FOXP1, EGR1, EGR2 and EGR3 may bind to the methylation sites above. Therefore, we speculated that abnormal methylation status of these CpGs might alter the structure of the transcription factor binding region, and thereby change the expression level of RNF180. This speculation coincides with the molecular mechanism by which methylation affects transcription. Future researches are needed to elucidate the effect of methylation of RNF180-specific CpG sites on gene function and relevant mechanism.

In conclusion, for the first time, we located the functional two CpG sites in the RNF180 promoter region by combining the relationship between methylation rate and expression. It is further clarified that the methylation rate of M5(−148)(Chr5:64,165,959) and M27(−26)(Chr5:64,166,081) site can be independent biomarkers for prognosis of GC, with the optimal methylation rate threshold at 0.3 as a cut-off value. If the conclusions of this study can be verified in a large population, the molecular biology test kit can be developed targeting these two sites in clinic. In terms of precision medicine for GC, it will be helpful to guide clinical treatment and more advanced diagnosis through accurate detection and analysis.
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